Janux Therapeutics (JANX) Change in Receivables (2020 - 2026)

Janux Therapeutics (JANX) has 6 years of Change in Receivables data on file, last reported at $35.0 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at $35.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $42.0 million (up 459.75% YoY), and the FY2021 annual result was -$8.0 million, down 200.0% from the prior year.
• Change in Receivables advanced to $35.0 million in Q1 2026 per JANX's latest filing, from $7.0 million in the prior quarter.
• Over five years, Change in Receivables peaked at $35.0 million in Q1 2026 and troughed at -$750000.0 in Q2 2023.
• A 4-year average of $6.1 million and a median of $519000.0 in 2024 frame the typical range for Change in Receivables.
• On a YoY basis, Change in Receivables climbed as much as 1030.8% in 2024 and fell as far as 30.8% in 2024.
• A 4-year view of Change in Receivables shows it stood at -$500000.0 in 2022, then sank by 50.0% to -$750000.0 in 2023, then surged by 1030.8% to $7.0 million in 2024, then soared by 401.36% to $35.0 million in 2026.
• Business Quant data shows JANX's Change in Receivables at $35.0 million in Q1 2026, $7.0 million in Q2 2024, and $519000.0 in Q1 2024.